Author Archives: Tanner Thomas

2019/01/22 Reven News Press

Kevin McGovern Joins Reven’s Board of Directors. Reven announces Kevin McGovern as the newest addition to its Board of Directors. Kevin McGovern Press Release

2019/01/17 Reven News Press

Reven Hires Dr. James Carlson. Dr. James Carlson hired as Reven’s Executive Vice President of Development Dr. James Carlson Press Release here: Reven Press Release – 011719  

2019/01/15 Reven News Press

On January 15, 2019 Reven completed their single-ascending-dose (SAD)/ multiple-ascending-dose (MAD) Phase 1 Clinical Trial in the United States. Reven is now in the planning stage of their Phase 2 Clinical Trial that will be conducted in the United States … Read More

2019/01/15 Reven News Press

MAD Cohort 3 completed dosing on January 15, 2019.

2019/01/04 Reven News Press

Reven Hires Susan Moore. Susan Moore hired as Reven’s Senior Director of Regulatory and Clinical Affairs.

2019/01/08 Reven News Press

MAD Cohort 3 begins seven-day dosing period.

2018/12/19 Reven News Press

Reven Hires Natalie Pizzimenti. Natalie Pizzimenti hired as Reven’s Clinical Research Scientist.

2018/12/18 Reven News Press

MAD Cohort 2 completed dosing on December 18, 2018.

2018/12/11 Reven News Press

MAD Cohort 2 begins seven-day dosing period.

2018/12/05 Reven News Press

SAD Cohort 6C doses subjects; SAD Cohort 6 is completed.

2018/12/03 Reven News Press

Reven Hires Crysta Huszai. Crysta Huszai hired as Reven’s Quality Specialist.

2018/11/30 Reven News Press

SAD Cohort 6b dosing completed.

2018/11/27 Reven News Press

SAD Cohort 6 Underway. SAD Cohort 6A doses subjects.

2018/11/19 Reven News Press

MAD Cohort 1 Completed.

2018/11/13 Reven News Press

MAD Cohort 1 Begins. MAD Cohort 1 begins seven-day dosing period.